分子肿瘤诊断市场－全球产业规模、份额、趋势、竞争、机会和预测，按产品类型、技术、应用、癌症类型、最终用户、地区和竞争细分，2020-2030 年

2024年，全球分子肿瘤诊断市场规模达35.4亿美元，预计2030年将达78.4亿美元，预测期内复合年增长率为14.17%。由于慢性病（尤其是癌症）发生率的上升，市场正在迅速扩张，这推动了对先进诊断解决方案的需求。分子肿瘤诊断是指用于在分子层面检测癌症的专门检测，识别指示疾病存在的遗传物质、蛋白质和生物标记。这种方法有助于早期发现、标靶治疗和改善患者预后。认知度的提高、新一代定序 (NGS) 等技术的进步以及对个人化医疗的持续投资，都促进了市场的成长。此外，严格的监管框架和全球向精准肿瘤学的转变，正在推动分子诊断平台的创新。随着全球医疗保健系统强调早期发现和高效的疾病管理，分子肿瘤诊断市场在已开发地区和新兴地区都将持续扩张。

关键市场驱动因素

全球癌症发生率上升，早期检测需求增加

主要市场挑战

先进诊断技术成本高且难以取得

主要市场趋势

人工智慧和机器学习在分子诊断中的整合

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球分子肿瘤诊断市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依产品类型（仪器、试剂盒和分析、软体）
  • 依技术（萤光原位杂交 (FISH)、次世代定序 (NGS)、聚合酶炼式反应 (PCR)、免疫组织化学 (IHC)、流式细胞仪和其他技术）
  • 按应用（研究、临床）
  • 依癌症类型{实体肿瘤（乳腺癌、卵巢癌、前列腺癌、肺癌、大肠直肠癌和其他实体肿瘤）、血癌（淋巴瘤、白血病、多发性骨髓瘤和其他血液系统恶性肿瘤）}
  • 按最终用户（医院和诊断中心、参考实验室、製药和生物技术公司、学术和研究机构）
  • 按地区（北美、欧洲、亚太、南美、中东和非洲）
  • 按公司分类（2024）
• 市场地图
  • 依产品类型
  • 依技术
  • 按应用
  • 按癌症类型
  • 按最终用户
  • 按地区

第六章：北美分子肿瘤诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲分子肿瘤诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区分子肿瘤诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳洲

第九章：南美洲分子肿瘤诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东与非洲分子肿瘤诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 阿联酋
  • 沙乌地阿拉伯
  • 南非

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如有）
• 最新动态

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品/服务的威胁

第 14 章：全球分子肿瘤诊断市场：SWOT 分析

第 15 章：竞争格局

• Sysmex Corporation
• F. Hoffmann-La Roche Ltd.
• Myriad Genetics, Inc.
• HTG Molecular Diagnostics, Inc.
• Danaher Corporation
• QIAGEN NV
• Bio-Rad Laboratories, Inc.
• Agilent Technologies, Inc.
• Illumina, Inc.
• Bayer AG

第 16 章：策略建议

第17章调查会社について・免责事项

The Global Molecular Oncology Diagnostics Market was valued at USD 3.54 billion in 2024 and is projected to reach USD 7.84 billion by 2030, growing at a CAGR of 14.17% during the forecast period. The market is expanding rapidly due to the rising incidence of chronic diseases, particularly cancer, which is driving the demand for advanced diagnostic solutions. Molecular oncology diagnostics refer to specialized tests used to detect cancer at the molecular level, identifying genetic materials, proteins, and biomarkers that signal the presence of disease. This approach supports early detection, targeted therapy, and improved patient outcomes. Increased awareness, advances in technology such as next-generation sequencing (NGS), and growing investments in personalized medicine are all contributing to market growth. In addition, stringent regulatory frameworks and a global shift toward precision oncology are encouraging innovation in molecular diagnostic platforms. As healthcare systems worldwide emphasize early detection and efficient disease management, the molecular oncology diagnostics market is poised for sustained expansion across developed and emerging regions.

Key Market Drivers

Increasing Global Cancer Incidence and Demand for Early Detection

The rising global prevalence of cancer is a major factor propelling growth in the molecular oncology diagnostics market. According to the World Health Organization (WHO), nearly 10 million people died from cancer in 2020, with the incidence rate expected to rise by 47% by 2040, reaching over 28 million new cases annually. This alarming increase has led to a heightened focus on early detection and precision diagnostics to improve treatment outcomes and reduce healthcare burdens. Molecular diagnostics offer a pathway for identifying cancer-related mutations, chromosomal changes, and gene expression profiles even before clinical symptoms appear. Technologies like PCR, NGS, and microarrays are pivotal in enabling personalized treatment strategies and enhancing prognosis accuracy. Governments and research bodies are investing heavily in cancer diagnostics infrastructure; for example, the U.S. National Cancer Institute allocated over $7 billion in 2023 for cancer research, with a strong emphasis on molecular diagnostic tools. These developments underscore the growing importance of molecular oncology diagnostics in combating the global cancer burden.

Key Market Challenges

High Cost and Limited Accessibility of Advanced Diagnostic Technologies

Despite technological progress, the high cost of molecular oncology diagnostics remains a critical barrier to widespread adoption. Advanced testing methods like next-generation sequencing and multiplex PCR panels require expensive reagents, equipment, and skilled professionals, making them inaccessible in many low- and middle-income countries. A single NGS test can cost between $1,000 and $5,000, limiting affordability for patients and straining underfunded healthcare systems. Furthermore, insufficient diagnostic infrastructure, particularly in rural areas, exacerbates disparities in healthcare access. Challenges include a lack of molecular pathology labs, inadequate cold chain systems, and a shortage of trained personnel. Even in developed nations, inconsistent reimbursement policies hinder the adoption of newer molecular tests. According to the World Bank, healthcare expenditure in low-income nations averages about 5% of GDP, compared to more than 10% in high-income countries. This disparity underscores the urgent need for policy support, public-private partnerships, and cost-reduction strategies to bridge the accessibility gap in molecular diagnostics.

Key Market Trends

Integration of Artificial Intelligence and Machine Learning in Molecular Diagnostics

A transformative trend in the molecular oncology diagnostics market is the integration of artificial intelligence (AI) and machine learning (ML) technologies to streamline and enhance genomic data analysis. As diagnostic platforms generate increasingly complex datasets, AI and ML provide tools to analyze patterns, classify cancer subtypes, and predict patient responses more accurately and rapidly than manual methods. These technologies can process thousands of variants simultaneously, identifying clinically relevant mutations and helping in treatment selection. Deep learning models are also being used to enhance the accuracy of image-based diagnostics and to interpret multi-omics data in real-time. Governments are supporting AI development through major funding initiatives, such as the NIH's Bridge2AI program in the U.S. and the UK's Industrial Strategy Challenge Fund. These efforts are catalyzing the adoption of AI-driven diagnostics, making molecular oncology testing more efficient, scalable, and accessible across the globe.

Key Market Players

• Sysmex Corporation
• F. Hoffmann-La Roche Ltd.
• Myriad Genetics, Inc.
• HTG Molecular Diagnostics, Inc.
• Danaher Corporation
• QIAGEN N.V.
• Bio-Rad Laboratories, Inc.
• Agilent Technologies, Inc.
• Illumina, Inc.
• Bayer AG

Report Scope:

In this report, the Global Molecular Oncology Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Molecular Oncology Diagnostics Market, By Product Type:

• Instruments
• Kits and Assays
• Software

Molecular Oncology Diagnostics Market, By Technology:

• Fluorescence In-Situ Hybridization (FISH)
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Immunohistochemistry (IHC)
• Flow Cytometry
• Other Technologies

Molecular Oncology Diagnostics Market, By Application:

• Research
• Clinical

Molecular Oncology Diagnostics Market, By Cancer Type:

• Solid Tumor (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Other Solid Tumors)
• Blood Cancers (Lymphoma, Leukemia, Multiple Myeloma, and other Hematological Malignancies)

Molecular Oncology Diagnostics Market, By End User:

• Hospitals and Diagnostic Centers
• Reference Laboratories
• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes

Molecular Oncology Diagnostics Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Molecular Oncology Diagnostics Market.

Available Customizations:

Global Molecular Oncology Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Molecular Oncology Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Instruments, Kits and Assays, Software)
  • 5.2.2. By Technology (Fluorescence In-Situ Hybridization (FISH), Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Flow Cytometry, and Other Technologies)
  • 5.2.3. By Application (Research, Clinical)
  • 5.2.4. By Cancer Type {Solid Tumor (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Other Solid Tumors), Blood cancers (Lymphoma, Leukemia, Multiple Myeloma, and other Hematological Malignancies)}
  • 5.2.5. By End User (Hospitals and Diagnostic Centers, Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes)
  • 5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East, and Africa)
  • 5.2.7. By Company (2024)
• 5.3. Market Map
  • 5.3.1. By Product Type
  • 5.3.2. By Technology
  • 5.3.3. By Application
  • 5.3.4. By Cancer Type
  • 5.3.5. By End User
  • 5.3.6. By Region

6. North America Molecular Oncology Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By Cancer Type
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Molecular Oncology Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By Cancer Type
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Molecular Oncology Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By Cancer Type
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Molecular Oncology Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By Cancer Type
      • 6.3.3.2.5. By End User

7. Europe Molecular Oncology Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By Cancer Type
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Molecular Oncology Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By Cancer Type
      • 7.3.1.2.5. By End User
  • 7.3.2. France Molecular Oncology Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By Cancer Type
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Molecular Oncology Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By Cancer Type
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Molecular Oncology Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By Cancer Type
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Molecular Oncology Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By Cancer Type
      • 7.3.5.2.5. By End User

8. Asia-Pacific Molecular Oncology Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By Cancer Type
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Molecular Oncology Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By Cancer Type
      • 8.3.1.2.5. By End User
  • 8.3.2. Japan Molecular Oncology Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By Cancer Type
      • 8.3.2.2.5. By End User
  • 8.3.3. India Molecular Oncology Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By Cancer Type
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Molecular Oncology Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By Cancer Type
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Molecular Oncology Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By Cancer Type
      • 8.3.5.2.5. By End User

9. South America Molecular Oncology Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By Cancer Type
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Molecular Oncology Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By Cancer Type
      • 9.3.1.2.5. By End User
  • 9.3.2. Argentina Molecular Oncology Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By Cancer Type
      • 9.3.2.2.5. By End User
  • 9.3.3. Colombia Molecular Oncology Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By Cancer Type
      • 9.3.3.2.5. By End User

10. Middle East and Africa Molecular Oncology Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By Cancer Type
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. UAE Molecular Oncology Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By Cancer Type
      • 10.3.1.2.5. By End User
  • 10.3.2. Saudi Arabia Molecular Oncology Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By Cancer Type
      • 10.3.2.2.5. By End User
  • 10.3.3. South Africa Molecular Oncology Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By Cancer Type
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products/Services

14. Global Molecular Oncology Diagnostics Market: SWOT Analysis

15. Competitive Landscape

• 15.1. Sysmex Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. F. Hoffmann-La Roche Ltd.
• 15.3. Myriad Genetics, Inc.
• 15.4. HTG Molecular Diagnostics, Inc.
• 15.5. Danaher Corporation
• 15.6. QIAGEN N.V.
• 15.7. Bio-Rad Laboratories, Inc.
• 15.8. Agilent Technologies, Inc.
• 15.9. Illumina, Inc.
• 15.10. Bayer AG

16. Strategic Recommendations

17. About Us & Disclaimer